We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in Seelos Therapeutics, Inc. Common Stock in 2025 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $4.77K → $0 (-$4.77K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
–
Holders Change
-2
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
AI
AdvisorShares Investments
Maryland
-$4.77K
2
VWWMG
Vermillion & White Wealth Management Group
Pennsylvania
-$2
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
1
AdvisorShares Investments
Maryland
– -$4.77K -20,543 Closed
VWWMG
2
Vermillion & White Wealth Management Group
Pennsylvania
– -$2 -7 Closed

SEEL Hedge Fund Activity: Q1 2025 in Review

0 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q1 2025, worth a combined $0 — down 100% from $4.77K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of SEEL and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was AdvisorShares Investments, exiting entirely with an estimated $4.77K sold.

  • 0 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q1 2025, down from 2 in Q4 2024.
  • Funds reported $0 of Seelos Therapeutics, Inc. Common Stock stock for Q1 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q1 2025 and 2 closed out, a net change of -2 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q1 2025 was AdvisorShares Investments, an estimated $4.77K sold.

Based on aggregated 13F filings for Q1 2025.